Monitor upcoming data readouts at CTAD 2026 (nfvPPA biomarkers) and RESTORE stroke trial topline results by year-end; these are key catalysts that could validate neflamapimod's broader therapeutic potential beyond DLB. The company's cash runway through Q3 2027 provides visibility but a partnership for DLB Phase 3 is critical for funding and de-risking the program.
Drug in focus
CRVO drug pipeline →neflamapimod
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2b completed; Phase 3 planned but not yet initiated
- Time to market
- At least 3-4 years, assuming a partnership is secured, Phase 3 initiates in H2 2026, completes enrollment and reads out (~2 years), then NDA submission and FDA review (~1 year).
- Next catalyst
- None dated
What to watchWatch for a strategic partnership announcement to fund the Phase 3 DLB trial, this is the single biggest near-term catalyst and would validate the drug's commercial potential. However, be aware of heavy recent dilution (~$20.5M raised in June 2026), an S-3 resale shelf overhang, and the risk that Phase 3 may not begin without a partner. The stock trades near the low end of its 52-week range ($2.13-$13.13) with a ~$28M market cap; analyst mean target is $19.50 but these targets were set before the latest dilutive financings.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $1.43entry
- T+1 · 7d ago −4.20%α −3.83% · $1.37
- T+5 · 16h ago +16.78%α +18.48% · $1.67
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CervoMed reported a Q3 2026 net loss of $5.9M, narrower than the $7.7M loss in Q3 2025, driven by lower R&D spending after the completion of its Phase 2b RewinD-LB trial. The company had $19.6M in cash, expected to fund operations through Q3 2027. Key upcoming catalysts include 24-week biomarker data from the nfvPPA Phase 2a trial at CTAD 2026 and topline data from the RESTORE stroke trial by year-end 2026.
Key Financial Metrics
Key Facts
- Net loss of $5.9M for Q3 2026 vs $7.7M in Q3 2025
- Cash and marketable securities of $19.6M as of Sep 30, 2026, expected to fund operations through Q3 2027
- No grant revenue recognized in Q3 2026 vs $0.3M in Q3 2025, due to completion of RewinD-LB trial
- R&D expenses decreased to $3.7M from $6.0M year-over-year
- 24-week biomarker data from nfvPPA Phase 2a trial selected for presentation at CTAD 2026 (Nov 16-19)
- Topline data from Phase 2a RESTORE stroke trial expected by end of 2026
- First patient dosing in EXPERTS-ALS trial expected in Q1 2027
- Company seeking strategic partnership to advance neflamapimod into Phase 3 for DLB
Financial Impact
Net loss improved by $1.8M year-over-year; cash burn rate approximately $1.3M per month in Q3 2026
Risk Factors
- No revenue and reliance on cash reserves; going concern risk if partnership or financing not secured
- Clinical trial failure in any of the three ongoing programs (DLB, nfvPPA, RAS, ALS) could impair value
- Dependence on finding a strategic partner for DLB Phase 3; no guarantee of favorable terms or timing
- Small market cap ($23M) amplifies volatility on binary clinical events
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398299 |
Track record
26 reports on CRVO
12 of 13 bullish or bearish reports moved the stock their way by T+1. Best: +40.68% at T+60 after the Jun 18, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 4/10 Entry $1.74 Now $1.67 −3.75% settles Nov 18
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $1.43 to $1.37 Now $1.67 +16.78% ▼ −4.20% −3.83% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $1.60 to $1.64 Now $1.67 +4.37% ▲ +2.50% +2.98% vs SPY
- Oct 14, 20264w ago 8-K Neutral 2/10 Entry $2.25 to $2.24 Now $1.67 −25.78% ▼ −0.44% +0.66% vs SPY
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.27 to $2.29 Now $1.67 −26.43% ▲ +0.88% +1.96% vs SPY
- Oct 9, 20265w ago 8-K Neutral 2/10 Entry $2.51 to $2.27 Now $1.67 −33.47% ▼ −9.56% −9.55% vs SPY
- Sep 10, 20269w ago Press Release Bullish 5/10 Entry $2.48 to $2.57 Now $1.67 −32.66% ▲ +3.63% +2.78% vs SPY
- Aug 10, 202614w ago 8-K Neutral 4/10 Entry $3.09 to $3.07 Now $1.67 −45.95% ▼ −0.65% −0.90% vs SPY
- Aug 4, 202614w ago 8-K Bullish 6/10 Entry $2.80 to $2.81 Now $1.67 −40.36% ▲ +0.36% +0.56% vs SPY
- Aug 4, 202614w ago Press Release Bullish 4/10 Entry $2.80 to $2.81 Now $1.67 −40.36% ▲ +0.36% +0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers